Very High HDL Associated With CV Mortality in CAD
|
By LabMedica International staff writers Posted on 31 May 2022 |

Coronary artery disease (CAD) is a common heart condition. The major blood vessels that supply the heart (coronary arteries) struggle to send enough blood, oxygen and nutrients to the heart muscle. Cholesterol deposits (plaques) in the heart arteries and inflammation are usually the cause of CAD.
High-density lipoprotein (HDL) cholesterol is known as the "good" cholesterol because it helps remove other forms of cholesterol from your bloodstream. Higher levels of HDL cholesterol are associated with a lower risk of heart disease. However, recent data in the general population have shown increased risk of adverse outcomes at very high HDL-C concentrations.
Cardiologists at the Emory University School of Medicine (Atlanta, Georgia) and their colleagues studied the association between very high HDL-C levels (>80 mg/dL) and mortality in patients with CAD and to investigate the association of known HDL-C genotypes with high HDL-C level outcomes. In a prospective study, they analyzed data from patients with confirmed CAD and high HDL, defined as at least 80 mg/dL, using UK Biobank (2006-present; n = 14,478; mean age, 62 years; 76.2% men) and Emory Cardiovascular Biobank (2003-present; n = 5,467; mean age, 64 years; 66.4% men).
During a median follow-up of 8.9 years in the UK Biobank and 6.7 years in the Emory Cardiovascular Biobank, the scientists observed a U-shaped association between HDL level, all-cause death and CV death, with higher risk among patients with low and very high HDL versus patients with midrange values. For the UK Biobank analysis, compared with patients with an HDL between 40 mg/dL and 60 mg/dL, patients with an HDL of at least 80 mg/dL were nearly twice as likely to die of any cause during follow-up, with a HR of 1.96 and 71% more likely to die of CV causes, with an HR of 1.71. Results persisted after adjustment for other CV risk factors, including hypertension, diabetes and smoking. In sensitivity analyses, all-cause death risk among patients from the UK Biobank with very high HDL was greater among men (HR = 2.63) compared with women (HR = 1.39).
Arshed A. Quyyumi, MD, FRCP, a Professor of Medicine and senior author of the study, said, “Very high HDL levels are associated with increased risk for adverse outcomes, not lower risk, as previously thought. This is true not only in the general population but also in people with known coronary artery disease. The higher risk with very high HDL levels is particularly seen in men, although women also have higher risk at very high HDL levels.”
The authors concluded that results of their cohort study suggest that very high HDL-C levels are paradoxically associated with higher mortality risk in individuals with CAD. This association was independent of the common polymorphisms associated with high HDL-C levels. The study was published on May 18, 2022 in the journal JAMA Cardiology.
Related Links:
Emory University School of Medicine
Latest Clinical Chem. News
- Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain
- First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage
- Multi-Cancer Blood Test Expands Detection to Cancers Lacking Routine Screening Options
- Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes
- Blood Test Patterns Improve Cancer Risk Assessment in Primary Care
- Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection
- Machine Learning Supports Targeted Screening for Elevated Lipoprotein(a)
- Blood Antibody Linked to Lower Depression and PTSD Symptoms After Brain Injury
- Blood Biomarker May Help Monitor Early Response to Lecanemab in Alzheimer’s Disease
- New Reference Material Aims to Improve Comparability of Angiotensin II Testing
- Childhood Blood Biomarkers May Reveal Early Heart, Kidney, and Metabolic Risks
- Blood Biomarker Study Reveals Early Signals of Future Cognitive Difficulties
- International Consensus Guidance Outlines General Population Screening for Early-Stage Type 1 Diabetes
- Electrical Fingerprint of Extracellular Vesicles Could Detect Pancreatic Cancer
- Algorithm Uses Blood Biomarkers to Improve Alzheimer’s Trial Screening
- Blood Biomarker May Track Bone Metastases in Medullary Thyroid Cancer
Channels
Molecular Diagnostics
view channel
Genetic Testing Program Helps Uncover Inherited Risk in Pediatric Cancer
Inherited cancer risk can affect children, adolescents and young adults, but it may not always be apparent from tumor type or family history alone. Some cancer syndromes require specialized expertise and... Read more
Genomic Breast Cancer Study Adds Real-World Evidence Across Diverse Patient Populations
Early-stage breast cancer treatment planning requires balancing recurrence risk, tumor biology, and the potential benefit of systemic therapy. These decisions can be challenging when certain patient groups... Read more
Computational Filters Enhance Metagenomic Detection of Meningitis and Encephalitis
Infections of the central nervous system, such as meningitis and encephalitis, can be severe and require prompt diagnosis and treatment. Clinicians typically evaluate cerebrospinal fluid alongside symptoms... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read moreImmunology
view channel
Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent
Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more
Blood Biomarker May Predict Colitis Risk in Checkpoint Inhibitor Therapy
Immune checkpoint inhibitors can trigger immune-related colitis that leads to severe diarrhea, abdominal pain, and treatment interruptions. Clinicians currently lack validated tools to identify which patients... Read more
Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead
Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read moreMicrobiology
view channel
FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more
New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read morePathology
view channel
Simple Test Could Reduce the Need for Invasive Uterine Cancer Checks
Bleeding after menopause requires prompt investigation for uterine cancer, although most women who undergo testing do not have the disease. In the U.K., uterine cancer affects nearly 10,000 women each... Read more
Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival
Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more
Multimodal AI Improves Breast Cancer Recurrence Risk Prediction Beyond Standard Genomic Testing
Predicting which patients with early-stage breast cancer will develop distant recurrence remains difficult, complicating decisions about long-term therapy and surveillance. Widely used genomic assays are... Read moreTechnology
view channel
ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more
Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions
Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more
New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read moreIndustry
view channel
Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
Mayo Clinic Laboratories and Pathology Asia Holdings (PAH), together with subsidiary LifeStrands Genomics, announced a strategic investment and collaboration focused on expanding access to advanced diagnostics... Read more







